Medy-Tox Inc. (KOSDAQ: 086900)

Market Cap	803.79B
Revenue (ttm)	241.45B
Net Income (ttm)	10.73B
Shares Out	6.66M
EPS (ttm)	1,609.18
PE Ratio	75.01
Forward PE	18.50
Dividend	1,100.00 (0.95%)
Ex-Dividend Date	Sep 27, 2024

Volume	30,841
Average Volume	39,208
Open	120,700
Previous Close	120,700
Day's Range	119,900 - 121,800
52-Week Range	112,100 - 218,000
Beta	0.44
RSI	44.26
Earnings Date	Mar 24, 2025

About Medy-Tox

Medy-Tox Inc. operates as a biopharmaceutical company in South Korea. It provides botulinum toxin products, including Neuronox, a lyophilized white power for injection that is used to treat foot deformities due to spasticity in pediatric cerebral palsy patients; INNOTOX, a colorless transparent liquid-filled injection that is used to temporarily improve moderate to severe glabellar wrinkles; and Coretox, a lyophilized white power for injection that is used to temporarily improve moderate to severe glabellar wrinkles. The company also offers hya...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2000
• Employees: 721
• Stock Exchange: KOSDAQ
• Ticker Symbol: 086900

Financial Performance

In 2023, Medy-Tox's revenue was 221.12 billion, an increase of 13.34% compared to the previous year's 195.10 billion. Earnings were 8.78 billion, a decrease of -75.63%.